Xgeva approved for rare, non-malignant tumor
(HealthDay)—Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor that's most often non-cancerous.
Jun 13, 2013
not rated yet |
0